Prostate cancer pain management: EAU guidelines on pain management

World Journal of Urology

Volumn 30, Issue 5, 2012, Pages 677-686

  Bader, Pia ^a   Echtle, Dieter ^b   Fonteyne, Valerie ^c   Livadas, Kostas ^d   de Meerleer, Gert ^c   Paez Borda, Alvaro ^e   Papaioannou, Eleni G ^d   Vranken, Jan H ^f  

^a STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

^b Staedtische Kliniken Moenchengladbach GmbH   (Germany)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^e HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^f Medical Centre Alkmaar   (Netherlands)

Author keywords

Biphosphonates; Corticosteroids; EAU guidelines; Pain; Pharmacotherapy; Prostate cancer; Radionuclides; Radiotherapy; Surgery

Indexed keywords

ANALGESIC AGENT;

ANALGESIA; ANIMAL; CHEMORADIOTHERAPY; CHRONIC PAIN; EUROPE; MALE; METHODOLOGY; PAIN; PALLIATIVE THERAPY; PRACTICE GUIDELINE; PROSTATE TUMOR; REVIEW; STANDARD;

ACUTE PAIN; ANALGESICS; ANIMALS; CHEMORADIOTHERAPY; CHRONIC PAIN; EUROPE; MALE; PAIN MANAGEMENT; PALLIATIVE CARE; PRACTICE GUIDELINES AS TOPIC; PROSTATIC NEOPLASMS;

EID: 84868560459     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-012-0825-1     Document Type: Review

References (59)

1. Oxford Centre for Evidence-Based Medicine Levels of Evidence (2001) Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, Martin Dawes since November 1998. Updated by Jeremy Howick, March 2009. Centre for Evidence Based Medicine Web site. http://www. cebm. net/index. aspx?o=5653. Accessed Apr 2011.
2. Foley KM (1979) Pain syndromes in patients with cancer. In: Bonica JJ, Ventafridda V (eds) Advances in pain research and therapy 2. Raven Press, New York, pp 59-75.
3. Twycross RG, Lack SA (1983) Symptom control in far advanced cancer: pain relief. Pitman, London, p 6.
4. Jensen MP (2003) The validity and reliability of pain measures in adults with cancer. J Pain 4(1): 2-21.
5. Rosier EM, Iadarola MJ, Coghill RC (2002) Reproducibility of pain measurement and pain perception. Pain 98(1-2): 205-216.
6. Melzack R (1975) The McGill pain questionnaire: major properties and scoring methods. Pain 1: 277-299.
7. Mercadante S (1997) Malignant bone pain: pathophysiology and treatment. Pain 69(1-2): 1-18.
8. Zech DF, Grond S, Lynch J, Hertel D, Lehmann KA (1995) Validation of the world health organization guidelines for cancer pain relief: a 10-year prospective study. Pain 63: 65-76.
9. Caraceni A, Portenoy RK (1999) An international survey of cancer pain, characteristics and syndromes. Pain 82: 263-274.
10. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, Hansson P, Hughes R, Nurmikko T, Serra J (2008) Neuropathic pian. Redefinition and a grading system for clinical and research purposes. Neurology 70: 1630-1635.
11. Rasmussen PV, Sindrup SH, Jensen TS, Bach FW (2004) Symptoms and signs in patients with suspected neuropathic pain. Pain 110: 461-469.
12. Kamat AM, Huang SF, Bermejo CE, Rosser CJ, Pettaway CA, Pisters PW, Guitreau DP, Pisters LL (2003) Total pelvic exenteration: effective palliation of perineal pain in patients with locally recurrent prostate cancer. J Urol 170(5): 1868-1871.
13. Wilson JR, Urwin GH, Stower MJ (2005) The role of percutaneous nephrostomy in malignant ureteric obstruction. Ann R Coll Surg Engl 87(1): 21-24.
14. Thompson JC, Wood J, Feuer D (2007) Prostate cancer: palliative care and pain relief. Br Med Bull 83: 341-354.
15. Ok JH, Meyers FJ, Evans CP (2005) Medical and surgical palliative care of patients with urological malignancies. J Urol 174: 1177-1182.
16. Russo P (2000) Urologic emergencies in the cancer patient. Semin Oncol 27(3): 284-298.
17. Schröder FH, Whelan P, de Reijke TM, Kurth KH, Pavone-Macaluso M, Mattelaer J, van Velthoven RF, Debois M (2004) Members of the EORTC Genito-Urinary Group Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892. Eur Urol 45(4): 457-464.
18. McQuay HJ, Collins SL, Carroll D (2000) Radiotherapy for the palliation of painful bone metastases. Cochrane Database Sys Rev 2: CD001793.
19. Wu J, Wong R, Johnston M et al (2003) Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiot Oncol Biol Physiol 55: 594-605.
20. Sze WM, Shelley M, Held I et al (2004) Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy. Cochrane Database Syst Rev 2: CD004721.
21. George R, Jeba J, Ramkumar G et al (2008) Interventions for the treatment of metastatic extradural spinal cord compression in adults. Cochrane Database Syst Rev 8(4): CD006716.
22. Klimo P, Thompson CJ, Kestle JRW et al (2005) A meta-analysis of surgery versus conventional radiotherapy for the treatment of metastatic spinal epidural disease. Neuro Oncol 7: 64-76.
23. Paes FM, Serafini AN (2010) Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain. Semin Nucl Med 40: 89-104.
24. Krishnamurthy GT, Krishnamurthy S (2000) Radionuclides for metastatic bone pain palliation: a need for rational re-evaluation in the new millennium. J Nucl Med 41(4): 688-691.
25. Finlay IG, Mason MD, Shelley M (2005) Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol 6: 392-400.
26. Resche I, Chatal JF, Pecking A, Ell P, Duchesne G, Rubens R, Fogelman I, Houston S, Fauser A, Fischer M, Wilkins D (1997) A dose-controlled study of 153Sm- ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 33: 1583-1591.
27. Bodei L, Lam M, Chiesa C, Flux G, Brans B, Chiti A (2008) Giammarile. European Association of Nuclear medicine (EANM): EANM procedure guidelines for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging 35(10): 1934-1940.
28. Saad H, Higano C, Sartor O, Colombel M, Murray R, Mason MD, Tubaro A, Schulman C (2006) The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel. Clin Genitourin Cancer 4(4): 257-262.
29. Smith MR (2005) Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence. Cancer Treat Rev 31(Suppl. 3): 19-25.
30. Michaelson MD, Smith MR (2005) Bisphosphonates for treatment and prevention of bone metastases. J Clin Oncol 23(32): 8219-8224.
31. Shih A, Jackson KC, II (2007) Role of corticosteroids in palliative care. J Pain Palliat Care Pharmacother 21(4): 69-76.
32. Berthold DR, Pond GR, Roessner M, de Wit R, Eisenberger M (2008) TAX-327 investigators. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 14(9): 2763-2767.
33. World Health Organization (1990) Cancer pain relief and palliative Care. Report of a WHO expert committee. World Health Organization Technical Report Series, 804. Geneva, Switzerland: World Health Organization.
34. Grond S, Zech D, Schug SA, Lynch J, Lehman KA (1991) Validation of the world health organization guidelines for cancer pain relief during the last days and hours of life. J Pain Symptom Manage 6(7): 411-422.
35. Maltoni M, Scarpi E, Modonesi C et al (2005) A validation study of the WHO analgesic ladder: a two-step vs three-step strategy. Supp Care Cancer 13: 888-894.
36. Miguel R (2000) Interventional treatment of cancer pain: the fourth step in the World Health Organization analgesic ladder? Cancer Control 7: 149-156.
37. Vranken JH (2003) The palliative treatment with catheter techniques of intractable cancer pain: fourth step in the World Health Organization analgesic ladder. In: Recent Research development in Anesthesia & Analgesia. Transworld Research Network, Kerala, pp 59-71.
38. Drew J, Stambaugh JE Jr (1988) The combination of ibuprofen and oxycodone/acetaminophen in the management of chronic cancer pain. Clin Pharmacol Ther 44(6): 665-669.
39. Fitzgerald GA (2002) Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations. Am J Cardiol 89(6A): 26D-32D.
40. Schug SA, Sidebotham DA, Mc Guinnety M, Thomas J, Fox L (1998) Acetaminophen as an adjunct to morphine by patient-controlled analgesia in the management of acute postoperative pain. Anesth Analg 87(2): 368-372.
41. Stamer UM, Stüber F (2007) Genetic factors in pain and its treatment. Curr Opin Anaesthesiol 20(5): 478-484.
42. Hanning CD (1990) The rectal absorption of opioids. In: Benedetti C, Chapman C R, Giron G (eds) Opioid analgesia. Advances in pain research and therapy, vol 14. Raven Press, New York, pp 259-269.
43. Clark AJ, Ahmedzai SH, Allan LG, Camacho F, Horbay GL, Richarz U, Simpson K (2004) Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Curr Med Res Opin 20(9): 1419-1428.
44. Ahmedzai S, Brooks D (1997) Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. J Pain Symptom Manage 13(5): 254-261.
45. Coluzzi PH, Schwartzberg L, Conroy JD, Charapata S, Gay M, Busch MA, Chavez J, Ashley J, Lebo D, McCracken M, Portenoy RK (2001) Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 91(1-2): 123-130.
46. Saarto T, Wiffen PJ (2007) Antidepressants for neuropathic pain. Cochrane Database Syst Rev 4: CD005454.
47. Greenberg DB (1991) Strategic use of benzodiazepines in cancer patients. Oncology (Williston Park). 5(4): 83-88; discussion 88, 90, 95.
48. Caraceni A, Zecca E, Bonezzi C et al (2004) Gabapentin for neuropathic cancer pain: a randomized controlled trial from the gabapentin cancer pain study group. J Clin Oncol 22: 2909-2917.
49. Bell R, Eccleston C, Kalso E (2003) Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev 1: CD003351.
50. Douglas I, Bush D (1999) The use of patient-controlled boluses of local anaesthetic via a psoas sheath catheter in the management of malignant pain. Pain 82: 105-107.
51. Vranken JH, van der Vegt MH, Ubags LH, Pijl AJ, Dzoljic M (2002) Continuous sacral nerve root block in the management of neuropathic cancer pain. Anesth Analg 95: 1724-1725.
52. van Dongen RT, Crul BJ, de Bock M (1993) Long-term intrathecal infusion of morphine/bupivacaine mixtures in the treatment of cancer pain: a retrospective analysis of 51 cases. Pain 55: 119-123.
53. van Dongen RTM, van Ee R, Crul BJP (1997) Neurologic impairment during long-term intrathecal infusion of bupivacaine in cancer patients; a sign of spinal cord compression. Pain 69: 205-209.
54. Plancarte R, de Leon Casasola OA, El Helaly M, Allende S, Lema MJ (1997) Neurolythic superior hypogastric plexus block for chronic pelvic pain associated with cancer. Reg Anesth 22(6): 562-568.
55. Saunders C (1987) The philosophy of terminal cancer care. Ann Acad Med Singapore 16(1): 151-154.
56. Nanton V, Docherty A, Meystre C, Dale J (2009) Finding a pathway: information and uncertainty along the prostate cancer patient journey. Br J Health Psychol 14: 437-458.
57. Thaxton L, Emshoff JG, Guessous O (2005) Prostate cancer support groups: a literature review. J Psychosoc Oncol 23(1): 25-40.
58. Velthuis MJ, Agasi-Idenburg SC, Aufdemkampe G, Wittink HM (2010) The effect of physical exercise on cancer-related fatigue during cancer treatment: a meta-analysis of randomised controlled trials. Clin Oncol (R Coll Radiol) 22(3): 208-221.
59. Segal RJ, Reid RD, Courneya KS, Malone SC, Parliament MB, Scott SG, Venner PM, Quinney HA, Jones LW, Slovinec D'Angelo ME, Wellset GA (2003) Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 21: 1653-1659.